Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC

Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis are the main therapeutic option for patients with advanced non‐small cell lung cancer (NSCLC) without a druggable oncogenic alteration. Nevertheless, only a portion of patients benefit from this type of treatment. Here, we assessed th...

Descripción completa

Detalles Bibliográficos
Autores principales: Carbonell, Caterina, Frigola, Joan, Pardo, Nuria, Callejo, Ana, Iranzo, Patricia, Valdivia, Augusto, Priano, Ilaria, Cedrés, Susana, Martinez‐Marti, Alex, Navarro, Alejandro, Lenza, Laura, Soleda, Mireia, Gonzalo‐Ruiz, Javier, Vivancos, Ana, Sansó, Miriam, Carcereny, Enric, Morán, Teresa, Amat, Ramon, Felip, Enriqueta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158763/
https://www.ncbi.nlm.nih.gov/pubmed/36852704
http://dx.doi.org/10.1002/1878-0261.13409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158763/
https://www.ncbi.nlm.nih.gov/pubmed/36852704
http://dx.doi.org/10.1002/1878-0261.13409

Ejemplares similares